Accessibility Menu
RxSight logo

RxSight(NASDAQ) RXST

Current Price$5.29
Market Cap$232.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-65%
5 YearN/A
1 Year-24%
1 Month+19%
RxSight last closing stock price
MetricPriceDate
Last closeUSD 5.612026-07-20
RxSight stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.87%USD 5.062026-07-13
1 month+18.6%USD 4.732026-06-18
3 month-20.87%USD 7.092026-04-21
Year to date-46.16%USD 10.422025-12-31
1 year-23.67%USD 7.352025-07-18
3 year-81.94%USD 31.062023-07-21
Since inception-64.94%USD 16.002021-07-30

RxSight Financials at a Glance

Market Cap

$232.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$127.48M

Net Income (TTM)

-$46.64M

EPS (TTM)

-$1.14

P/E Ratio

-4.94

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$5.29

Volume

20,760

Open

$5.53

Previous Close

$5.61

Daily Range

$5.29 - $5.59

52-Week Range

$4.48 - $13.22

Estimated Earnings Date

Aug 5, 2026

RXST News

Foolcom-Featured.png

RxSight (RXST) Q2 Loss Beats Estimates

Motley Fool Markets TeamAug 7, 2025

RXST: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RxSight

RxSight helps people see clearly after cataract surgery. Doctors adjust their special lenses using a light machine. Patients choose their preferred vision after the operation.

Custom Vision After Surgery

  • Light Adjustable Lens: Premium intraocular lens made of light-sensitive material; modified by doctors after surgical implantation to optimize visual outcomes.
  • Light Delivery Device: Office-based treatment system; delivers programmed ultraviolet light patterns to adjust the power of the implanted lens.
  • Service and Accessories: Maintenance for delivery devices and related medical parts; supports clinics using the light adjustable system.

A New Way to Sell

  • Changed the company name from Calhoun Vision to RxSight in February 2017.
  • Integrated clinical and sales teams into a single unified Customer Success Organization to manage doctor relationships.
  • Reached a total installed base of 1,154 light delivery devices as of March 31, 2026.
  • Implanted approximately 332,000 adjustable lenses from inception through the first quarter of 2026.

Why the Technology Matters

RxSight provides the only cataract technology that doctors adjust after the surgery ends. This system eliminates the uncertainty usually found when choosing lenses before an operation.

Recent Financial Performance

  • Sales hit $30.9 million in Q1 2026, down 18.5% from Q1 2025.
  • Gross profit was $23.5 million in Q1 2026, down 17.1% year-over-year.
  • Net loss deepened to $15.9 million in Q1 2026, worsened by 93.9% from 2025.
  • Free cash flow worsened to negative $11.7 million in Q1 2026, down 23.8% year-over-year.

Bottom Line

RxSight has transitioned from a development firm to a commercial provider of customizable medical devices. Its unique adjustable lens system targets the premium segment of the cataract surgery market.

AI Generated • May 19, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

461

CEO

Ronald M. Kurtz, MD

Website

rxsight.com

Headquarters

Aliso Viejo, CA 92656, US

RXST Financials

Key Financial Metrics (TTM)

Gross Margin

77.02%

Operating Margin

-43.42%

Net Income Margin

-36.58%

Return on Equity

-17.01%

Return on Capital

-16.81%

Return on Assets

-15.34%

Earnings Yield

-20.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$232.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.40M

Volume

20.76K

Avg. Volume

1.06M

Financials (TTM)

Gross Profit

$98.18M

Operating Income

-$55.35M

EBITDA

-$43.24M

Operating Cash Flow

-$17.57M

Capital Expenditure

-$4.01M

Free Cash Flow

-$21.58M

Cash & ST Invst.

$217.88M

Total Debt

$10.83M

RxSight Performance Analysis

RxSight annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 49,005,000116.9%
20232023-12-31USD 89,077,00081.8%
20242024-12-31USD 139,927,00057.1%
20252025-12-31USD 134,479,000-3.9%
RxSight sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-11.2%
Q32025-09-30-9.8%
Q42025-12-317.5%
Q12026-03-31-5.3%
RxSight annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.4135.6%
20232023-12-31USD -1.41-41.5%
20242024-12-31USD -0.71-49.9%
20252025-12-31USD -0.9535.0%
RxSight sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-45.0%
Q32025-09-3017.2%
Q42025-12-318.3%
Q12026-03-31-72.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$30.89M

-18.5%

Gross Profit

$23.50M

-17.1%

Gross Margin

76.06%

N/A

Market Cap

$232.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$503.76K

N/A

Employees

461

N/A

Net Income

-$15.88M

-93.9%

EBITDA

-$15.04M

-103.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$217.88M

-5.0%

Total Debt

$10.83M

-10.1%

Accounts Receivable

$22.44M

-27.5%

Inventory

$34.87M

+47.9%

Long Term Debt

$9.32M

-15.2%

Short Term Debt

$1.50M

+42.6%

Return on Assets

-15.34%

N/A

Return on Invested Capital

-20.01%

N/A

Free Cash Flow

-$11.65M

-23.8%

Operating Cash Flow

-$10.89M

-23.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TMCITreace Medical Concepts, Inc.
$4.21-0.59%
SMLRSemler Scientific, Inc.
$20.33-4.87%
DMACDiaMedica Therapeutics Inc.
$7.08+1.05%
DCTHDelcath Systems, Inc.
$12.82+1.83%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.09+0.01%
MARAMara Holdings
$12.39+0.06%
UTZUtz Brands
$14.09+0.89%
HLHecla Mining
$15.32+0.07%

Questions About RXST

What is the current price of RxSight?

RxSight is trading at $5.29 per share.

What is the 52-week range for RxSight?

Over the past 52 weeks, RxSight has traded between $4.48 and $13.22.

How much debt does RxSight have?

As of the most recent reporting period, RxSight reported total debt of $10.83M.

How much cash does RxSight have on hand?

RxSight reported $17.57M in cash and cash equivalents in its most recent financial results.

What is RxSight’s dividend yield?

RxSight does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services